Studien, an denen das Zentrum aktuell teilnimmt:

1. RamuNET
   Titel: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors.
   Phase: II
   Code: RamuNET
   EUDRACT-No.: 2017-001207-68
   
   
2. SORENTO
   Titel: A randomized, multi-center, open-label, active-controlled
   Phase 3 trial to assess the efficacy and safety of octreotide subcuta-neous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors
   Phase: III
   Code: SORENTO
   EUDRACT-No.: 2021-000849-40
   
   
3. COMPETE
   Titel: A prospective, randomized, controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Re-ceptor Radionuclide Therapy (PRRT) with 177 Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET)
   Phase: III
   Code: COMPETE
   EUDRACT-No.: 2016-001897-13